OPTN News and Press, OptiNose Inc. From 12/06/23

2023-12-06 08:22:11 ET More on OptiNose OptiNose, Inc. 2023 Q3 - Results - Earnings Call Presentation OptiNose, Inc. (OPTN) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on OptiNose Historical earnings data for OptiNose Financia...

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment ...

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35...

2023-11-09 10:04:02 ET OptiNose, Inc. (OPTN) Q3 2023 Earnings Conference Call November 9, 2023, 8:00 AM ET Company Participants Jonathan Neely - Vice President, Investor Relations and Business Development Dr. Ramy Mahmoud - Chief Executive Officer Paul Spence - C...

2023-11-09 07:08:54 ET More on OptiNose Seeking Alpha’s Quant Rating on OptiNose Historical earnings data for OptiNose Financial information for OptiNose For further details see: OptiNose GAAP EPS of -$0.08, revenue of $19.8M

Company reports third quarter 2023 XHANCE net revenue of $19.8 million and increases full year 2023 XHANCE net revenue guidance Strong improvement in operating efficiency as SG&A and R&D expenses decreased by $32M or 33% year-to-date PDUFA goal date for XHANC...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

OptiNose Inc. (OPTN) is expected to report $-0.1 for Q3 2023

YARDLEY, Pa., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2023 and corporate updates, befor...

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2...